Title: **Assessing Neuropsychiatric Symptoms in Long COVID: A Retrospective Cohort Study from a South Texas Long COVID Clinic**

Authors: Anne Marie Wells, MS[1,2]; Summer Rolin, PsyD[3,6]; Barbara Robles-Ramamurthy, MD[6]; Gabriela Gibson-Lopez, PsyD[4,6]; Martin Goros, MS[7], Jonathan A Gelfond, MD, PhD[7], Stephen Gelfond, MD[6], Philip Balfanz, MD, MBA[6]; Melissa Deuter, MD[6]; Donald McGeary, PhD[5,6]; Monica Verduzco-Gutierrez, MD[3,6]

Affiliations:

1. South Texas Medical Scientist Training Program, UT Health San Antonio, San Antonio, TX, USA
2. Department of Pharmacology, UT Health San Antonio, San Antonio, TX, USA
3. Department of Rehabilitation Medicine, UT Health San Antonio, TX, USA
4. Department of Family & Community Medicine, UT Health San Antonio, San Antonio, TX, USA
5. Department of Psychiatry & Behavioral Health Sciences, UT Health San Antonio, San Antonio, TX, USA
6. South Texas Psychiatry Practice-Based Research Network (PBRN), San Antonio, TX, USA
7. Department of Population Health Sciences, UT Health San Antonio, San Antonio, TX, USA

Corresponding Author:
Verduzco-Gutierrez; 7703 Floyd Curl Dr., Mail Code 7798, San Antonio, TX 78209

Key Words: PASC, Long COVID, PTSD, stress, depression, anxiety, PCL-5, GAD-7, PHQ-9

Tables: 3
Figures: 4
Supplement: Figures (2), Tables (1)

Author Contributions

SR, MVG, BRR, GGL, PB, MD, AMW and SG conceived the project, generated hypotheses, and supplied patient records for data collection. SR completed the application for IRB approval. JG, MG, SR, MVG, BRR, and AMW performed the data analysis. AMW wrote the manuscript. SR, MVG, AMW, JG, and DM revised and edited the manuscript. All authors reviewed and approved the final manuscript for submission.

Acknowledgements

This was a study completed by the interdisciplinary collaborations of the South Texas Psychiatry Practice-Based Research Network (PBRN). We would like to express our gratitude to the patients who entrusted our team with the data for this study. Our also extend our sincere gratitude to the many students who performed data collection and contributed to the development of poster presentations of this study (Anne Marie Wells, Richa Sinkre, Ashley Chakales, Sean Rumney, and Phillip Yang). Finally, we thank the South Texas Psychiatry PBRN staff, especially Kaitlyn Waxler, for their persistence and keeping the study organized.

Funding

This study (JG, MG) was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UM1 TR004538. The training for AMW was supported by F30MH134482, T32R004545, STX-MSTP (T32GM113896 / T32GM145432), T32NS082145, R25NS089462. MVG was supported by a grant from the Agency for Healthcare Research and Quality (AHRQ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Compliance with Ethical Standards

The authors have no disclosures.

57
58
59
60
61
62
63
64
65
66
67
68
69

Abstract

Long COVID, previously known as Post-Acute Sequelae of SARS-CoV-2 (PASC), refers to prolonged symptoms or diagnosable conditions following COVID-19 infection. The neuropsychiatric profile of Long COVID patients remains ambiguous. This study aimed to assess neuropsychiatric symptoms in a retrospective cohort of Long COVID patients (N = 162) at a Rehabilitation Medicine clinic in South Texas. Clinical data from patient records were used to calculate a Symptom Score, and screening tools for stress/PTSD (PCL-5), depression (PHQ-9), anxiety (GAD-7), and quality of life (SWL) were employed to evaluate if Long COVID duration and severity could predict neuropsychiatric outcomes. The majority were female (71%) and Hispanics (53%) who presented for treatment of Long COVID symptoms during the study period, including fatigue (93%), coughing/shortness of breath (81%), fever (67%), anosmia (58%), ageusia (54%), and weight loss (56%). A minority of participants were hospitalized (N = 49) or required ventilator support (N = 5) during acute infection. There was a high burden of neuropsychiatric symptoms, including subjective cognitive impairment (79%), headache (74%), and insomnia (58%). Symptom Score (median = 9, IQR [8,11]) was significantly correlated with increased depression (PHQ-9; $p < 0.05$), anxiety (GAD-7; $p < 0.05$) and elevated stress/PTSD (PCL-5; $p < 0.05$) symptoms. Long COVID patients taking stimulants or mood stabilizers had higher GAD-7 ($p < 0.031$, $p < 0.035$) and PHQ-9 ($p < 0.034$, $p < 0.009$) scores but not PCL-5 scores. Importantly, duration of Long COVID symptomatology also did not predict PCL-5 scores. No patient factors (e.g., sex, age, BMI, ethnicity) mediated Symptom Score. Nonetheless, historically marginalized groups, such as women and Hispanics, have been disproportionately affected by COVID-19. This study is the first to utilize validated screening tools to determine the presence and severity of neuropsychiatric symptoms in Long COVID patients. These findings may guide clinical management and future research on Long COVID, especially in historically excluded populations.

Scope Statement

We enthusiastically submit our Original Research article, entitled "**Assessing Neuropsychiatric Symptoms in Long COVID: A Retrospective Cohort Study from a South Texas Long COVID Clinic**" for consideration for publication in the journal Frontiers in Neurology. We believe the scope of our article aligns well with the scope and aim of the journal's Neurorehabilitation Section.

Long COVID is a debilitating neurological disorder with prominent and enduring cognitive and psychological impact. This study sought to characterize Long COVID symptoms from a cohort of patients at a Rehabilitation Medicine/Long COVID clinic in Southwest Texas. We stratified symptoms using validated psychiatric evaluation tools (e.g., PCL-5, GAD-7, PHQ-9, SWL) to determine if and to what extent psychiatric comorbidity exacerbated Long COVID symptoms. Our findings suggest that a Long COVID patient's depression, anxiety, and stress/post traumatic stress scores are highly correlated with other neurological symptoms. We advance the implementation of a Long COVID "Symptom Score", as well as the use of validated screening instruments to identify psychiatric features of Long COVID with the goal of maximizing life satisfaction and function over the course of treatment.

Introduction

The impact of the SARS-CoV-2 virus, which causes acute COVID-19 infection, is an ongoing public health concern in the United States (US) that is here to stay (1). Continued study of the multifaceted impact on health and longevity is essential to advance the development of effective therapeutic and prevention strategies. Most individuals recover from COVID-19 infection within 5-20 days, depending on severity of symptoms (2,3); yet, a recent meta-analysis (4) estimated 31-69% of COVID-19 patients endure ongoing, relapsing and remitting, or progressive symptoms beyond 30 days of primary infection. The resulting syndrome is known as Post-Acute Sequelae of SARS-CoV-2 (PASC) (5) or Long COVID. Thus, Long COVID is now defined by the National Academy of Sciences, Engineering, and Medicine as an infection-associated chronic condition that occurs after SARS-CoV-2 infection and is present for at least 3 months as a continuous, relapsing and remitting, or progressive disease state (6). Aggregated Long COVID symptomatology (5,7–9) has been tracked in both small (10) and large (9,11,12) longitudinal cohort studies. In addition to continued symptoms of the acute infection (e.g., coughing, shortness of breath, loss of taste and smell), all studies to date have identified a common clustering of symptoms primarily affecting neurologic or neuropsychiatric systems (4,5,9–12). These symptoms include chronic fatigue, cognitive impairment ("brain fog"), headache, pain syndromes, anxiety and depression. Given the neurovirulent profile of SARS-CoV-2 (13), one might predict that the neuropsychiatric burden of Long COVID contributes significantly to complex treatment need and delayed recovery of affected patients. In fact, most patients experience reduced health-related quality of life (14) and Long COVID neuropsychiatric cluster symptoms for at least 6 months and upwards of 3 years out from primary infection (9). Thus, Long COVID poses a significant and chronic disruption to patient lives, as demonstrated by increased disability and economic burden reported in this population (15).

Known risk factors (9,15–17) for Long COVID include those that predicate more severe COVID-19 infection, such as obesity, age, premorbid metabolic or cardiovascular conditions -- and, critically, healthcare equity and access. Historically excluded groups in the US, like women and Hispanics, have been disproportionately impacted by the COVID-19 pandemic (15–20). A recent multi-site study following over 12,000 patients (73% female) found that female sex was significantly associated with higher risk of Long COVID (21). While there are currently no large cohort studies following Hispanic-Americans, one study (22) sampling adults in Mexico found at least 5 persistent Long COVID symptoms in over half of participants (N = 192), with 360-day persistence probability of 0.78. Strikingly, the largest cohorts following the natural history of Long COVID in the US have disproportionately sampled Caucasian men (9,11). Thus, there may be significant gaps in our understanding of how various patient factors may impact the complexity and duration of Long COVID symptom clusters.

There are no cures nor adequate treatments for Long COVID apart from symptom management, perhaps due the complex, syndromic nature of the disorder. Importantly, studies published to date have relied entirely on self-reported neuropsychiatric symptoms without the support of validated screening tools that could facilitate uncovering the etiology of neuropsychiatric symptoms. There is a high degree of clinical utility in defining quantifiable metrics to expediate diagnosis and treatment of the neuropsychiatric burden of Long COVID.

We hypothesized that while chronic stress and anxiety do not directly facilitate the development of Long COVID, the presence and severity of neuropsychiatric symptoms should track with the core symptomatology and drive symptom complexity. Thus, we sought to characterize Long COVID symptoms in a cohort of patients (N = 162; 71% female, 53% Hispanic, median BMI = 30 [obese]) who presented in a Rehabilitation Medicine clinic in South Texas. We applied a proof-of-concept methodology to rapidly screen for major clusters of Long COVID symptomatology (i.e., "Symptom Score") that can be employed with a battery of widely used screening tools for comorbid stress, anxiety, and mood disorder neuropsychiatric symptoms. Our findings point to the high burden of fatigue, cognitive impairment, and anxiety measures in Long COVID patients that exacerbate the core Long COVID symptom profile. The associated impact on quality of life and risk of worsening psychiatric conditions demands greater attention to neuropsychiatric symptoms in the management of Long COVID patients, particularly in marginalized groups.

Results

Long COVID patients report high rates of fatigue with neuropsychiatric symptomatology

We characterized the self-reported symptom profile in Long COVID patients (N = 162), defined as symptoms or conditions present for at least 30 days after acute COVID-19 infection. Symptoms and conditions considered in this study were based on major categories determined by previous studies(5,9,11). The top-ranked symptoms within this cohort are summarized in Figure 1. Of note, 89% of the sample received an initial COVID-19 infection diagnosis by positive test (Fig 1). The distribution of approximate time elapsed since COVID-19 infection was approximately normal (Fig S1A). Of note, all patients received initial COVID-19 diagnosis within one of the major peaks of the COVID-19 pandemic (Fig S2).

The most common symptom reported in our cohort was fatigue (93%). At time of assessment, only 25% were currently exercising. Patients commonly reported myriad symptoms commonly associated with Long COVID fatigue(23), such as gastrointestinal (diarrhea [43%]), nausea/vomiting [38%], weight loss [58%]) and autoimmune (rash [21%]) symptoms. Most patients also reported a prolonged cluster of symptoms of acute COVID-19 infection, including coughing or shortness of breath (81%), fever (67%), loss of smell (58%), and loss of taste (54%).

The burden of neuropsychiatric symptoms in this cohort was striking. A substantial number of patients reported subjective cognitive impairment (79%), headache (74%), increased time spent in bed (73%), insomnia/sleep disturbance (58%). Many patients also reported new onset of muscle and/or joint pain (78%).

Importantly, we noted that very few patients with Long COVID symptoms in this cohort reported being hospitalized (N = 49) or requiring a ventilator (N = 5) during initial COVID-19 infection. Moreover, few required oxygen therapy or sustained cardiac damage because of COVID-19 infection. Thus, our cohort largely represents a patient group with Long COVID symptomatology following non-severe primary COVID-19 infection.

Patient factors do not predict Long COVID Symptom Score

We next sought to determine if patient factors predicted Long COVID symptom burden (Table 1). To this end, we ranked the incidences of self-reported symptoms or conditions present in our cohort. We then summed the total number of symptoms reported from the top 16-ranked symptoms for each patient as a Symptom Score. The median Symptom Score was 9 (IQR [8, 11]). We analyzed the relatedness of Symptom Scores across the cohort to patient factors. We also sought to determine if there were significant differences in patient factors between two subgroups divided by the median Symptom Score. We considered various patient factors, including biological sex, age, body mass index (BMI), race and ethnicity.

More female (N = 117, 73%) than male (N = 44, 27%) patients presented for evaluation for Long COVID symptoms during the study period. There was a higher proportion of females with above median symptom score compared to males, but this difference did not reach statistical significance (78% vs 68%, $p = 0.2$). Thus, despite significantly more females in our sample, there was no contribution of biological sex to Symptom Score. Moreover, age (median= 44, IQR [35, 54]) and BMI (median = 30, IQR [26,36]) also failed to predict Symptom Score ($p = 0.4$, 0.7, respectively). Likely due to the geographic location of this study, most patients identified as Hispanic (53%). Yet, no race or ethnicity identified in this cohort were associated with Symptom Score ($p = 0.8$).

Stress, anxiety, and satisfaction with life vary amongst Long COVID patients

Given the high contribution of neuropsychiatric symptoms to Symptom Score and disease burden, we sought to determine if the additional psychiatric symptoms could predict Symptom Score. In a first, we administered validated screening tools to assess the presence and severity of stress rising to the level of post-traumatic stress disorder (PTSD; PCL-5), anxiety (GAD-7), depression (PHQ-9), and general satisfaction with life (SWL).

The categorical score results across these screening tools are summarized in Table 2. PCL-5 score revealed 44% of the sample lived with stress-related symptoms that rise to the level of PTSD. We were unable to analyze this finding considering the index (inciting) traumatic event, and thus cannot attribute symptoms to Long COVID symptoms or COVID-19 infection specifically. GAD-7 scores demonstrated 69% of Long COVID patients demonstrated at least mild anxiety symptoms with 18% affected by severe anxiety. Most (74%) patients screened for depression with PHQ-9 had symptoms characterized by at

least mild depression with 28% experiencing moderately severe to severe symptoms. Of note, approximately 41% of the cohort was slightly to extremely dissatisfied with life.

We then sought to determine if Symptom Score informed stress and anxiety levels in this cohort by calculating Spearman rank correlations between each measure (Fig 2). PCL-5, GAD-7, and PHQ-9 scores were all mutually associated. Symptom Score was positively associated with PCL-5 ($r = 0.25$, $p < 0.05$), GAD-7 ($r = 0.29$, $p < 0.05$), and PHQ-9 ($r = 0.25$, $p < 0.05$) scores. Thus, the more complex Long COVID symptomatology, the worse stress, anxiety and depression symptoms a patient reported.

We refined this analysis to examine how each of the 20 items of the PCL-5 correlated with individual Long COVID symptoms that comprise the Symptom Score (Fig 3). Nearly all items on the PCL-5 were positively and significantly correlated with insomnia or sleep disturbance (17/20 items, $p < 0.05$). Importantly, individual item correlations do not vary by PTSD Symptom Cluster (B, C, D, E) as identified in the DSM-5. Headache (11/20 items, $p < 0.05$) and subjective cognitive impairment (9/20, $p < 0.05$) were also significantly positively correlated with many items. Of note, whether the patient was currently exercising at time of assessment was negatively correlated with 5 items ($p < 0.05$). The item most positively correlated with the greatest number of symptoms was item 8 *($p < 0.05$)*: "In the past month, how much were you bothered by: Trouble remembering important parts of the stressful experience?"

Pharmacotherapy may moderate stress and anxiety-related Long COVID symptoms

We sought to determine if any ongoing pharmacotherapy with Long COVID symptoms could explain the presence of stress and anxiety symptoms in our cohort. To this end, we performed a limited scope analysis by reviewing current prescriptions reported by each patient at the time of evaluation for Long COVID. Importantly, all medications reported were prescribed prior to the intake appointment without knowledge of prescription initiation or purpose of medication. We then correlated PHQ-9, GAD-7 and PCL-5 scores with classes of medications reported taking at the time of Long COVID evaluation. Of note, 41% of patients take medications related to respiratory care well after initial COVID-19 infection (Table S1). Although PHQ-9, PCL-5 and GAD-7 scores were all positively and significantly correlated with mood stabilizers and stimulant prescriptions (Fig 4), Long COVID patients taking either class of medication had significantly higher GAD-7 scores compared to those not taking them ($p = 0.031$ and 0.035, respectively; Table 3), without significant differences in PCL-5 scores. These results persisted with the background of high variability of duration of prescription prior to study intake.

Discussion

Despite the best efforts of public health and medical systems, the COVID-19 pandemic remains a burden in much of the world, underscoring the need for further research into both the impact of acute infection and its associated infection-associated chronic condition, known as Long COVID (2–5). SARS-CoV-2, the virus that causes COVID-19 and thus Long COVID, is neurotropic (24–27) and thus propagates throughout the central nervous system. The symptom clusters experienced by both acute COVID-19 and Long COVID patients imply significant distortions to normal functioning of central nervous system due to neurovirulent damage. In this study, we present key findings and acknowledge limitations, aiming to encourage others to build on this work to elucidate the underlying mechanisms of Long COVID and drive the development of effective therapies and interventions.

Symptom Score is an effective clinical tool for Long COVID evaluation and longitudinal tracking

We characterized Long COVID symptoms in a cohort of patients who, due to the unique nature of our study site in South Texas, represented categories of patients thought to be a greatest risk(4,16,17,20) for severe COVID-19 infection and thus Long COVID (N = 162; 71% female, 53% Hispanic, median BMI = 30). Additionally, in contrast to previous studies (9,12,20), few patients with Long COVID symptoms in our cohort were ever hospitalized (N = 49) or required ventilation (N = 5). Thus, while our cohort uniquely highlights the relative share of Long COVID patients presenting for treatment in this region, we emphasize the disproportionate burden faced by Long COVID patients with similar demographic profiles across the United States.

We used the Symptom Score to correlate burden and complexity of multisystemic Long COVID symptomatology, which demonstrated neuropsychiatric symptom clusters that are highly consistent with larger and more detailed inventories of Long COVID symptoms from previous studies.

Although relatively abbreviated, our findings align with attempts at deriving similar Symptom Scores in other large cohort studies (9,11,12) and reveal a high burden of fatigue, cognitive impairment, and anxiety among Long COVID patients, exacerbating the core Long COVID symptom profile. The significant impact on quality of life and the increased risk of worsening psychiatric disorders in Long COVID (28,29) underscore the need for greater attention to neuropsychiatric symptoms in the management of Long COVID. Thus, we advance the Long COVID Symptom Score as an effective inventory or core symptoms across several major systems (e.g., cognitive, respiratory, neuropsychiatric, pain, and constitutive/gastrointestinal symptoms) for use in clinical settings that benefit from rapid screening tools. We encourage clinicians and researchers to validate the Symptom Score in diverse populations. The Symptom Score may also assist with triaging patients for additional tests to detect neurovascular changes (30), neuroinflammation (31,32), and structural alterations (33–35) in patients with Long COVID.

Psychiatric comorbidity is more predictive of Long COVID severity than patient factors

We hypothesized that chronic stress and mood disorders may significantly contribute to the complexity of Long COVID symptomatology, playing a key role in the abnormal neuropathophysiology associated with the condition. Due to the retrospective nature of this study, we are unable to assign causality to the pre-infection presence of neurocognitive, neurological, or neuropsychiatric symptoms to the Long COVID syndrome. Yet, our study is the first to administer a battery of validated scales to track with Long COVID symptom burden, resulting in strong, significant correlations across the board. Moreover, we assert that the neuropsychiatric profile of Long COVID patients is complex and merits refined clinical evaluation as was undertaken with this cohort.

We found that comorbid stress and mood disorder symptomatology as measured by the PHQ-9, PCL-5 and GAD-7 inventories was more predictive of Long COVID symptomatology than any patient factor considered in this study. It is admittedly difficult to attribute stress, anxiety, or satisfaction with life measures specifically to COVID-19 infection or chronic Long COVID symptomatology without knowledge of any index or inciting traumatic events. We anticipate this may be a difficult confounding factor to address, given the general stress and anxiety levels induced by the global COVID-19 pandemic at the time of study recruitment. Yet, the presence of complex neuropsychiatric symptomatology is undeniable, and the use of these instruments in Long COVID patient assessment is not a standard component of clinical assessment in this population. We also identified patients with premorbid anxiety disorders, who were not excluded from this study based on the original criteria, that may serve as a refined subgroup for future analyses on changes in anxiety levels attributable to neuropsychiatric burden in Long COVID.

Future studies should include validated screening tools to enable quantification and thus more objective assessment of neuropsychiatric burden in Long COVID patients. This may aid the tracking of symptom progression over time. One gap in this study was access to an inventory to characterize symptoms related to the patient-reported cognitive impairment reported by 73% of our cohort at time of assessment. A standardized and validated tool to assess specific features of cognitive impairments in this and other populations could point to underlying neurobiological pathways or circuitry that are particularly vulnerable to neurovirulence of COVID-19 infection or chronic damage related to Long COVID.

Pharmacotherapy indexing remains a gap in establishing Long COVID causality

Not all patients with acute COVID-19 infection progress to develop Long COVID symptoms. While the cause of Long COVID syndrome following acute COVID-19 infection has yet to be established, there is some evidence that specific medication classes during acute phase confers elevated risk of Long COVID conversion (e.g., NSAIDs (36)). Nonetheless, we performed an exploratory analysis of patient-reported pharmacotherapy classes at study intake against scores on neuropsychiatric instruments since our results established a strong correlation to higher neuropsychiatric burden and Long COVID Symptom Score. Although we suspect our analysis ran against background variation in prescription initiation and duration prior to or concurrent with Long COVID onset, we found weak positive correlations with stimulant and mood stabilizing class prescriptions with higher neuropsychiatric battery scores. On the other hand, we found a weakly negative correlation with PHQ-9 scores and reported all-class blood pressure medications. We hope these results generate sufficient intrigue to merit study of pharmacotherapy as an index event for two motives: (1) to establish any additional risk or protective effects of pharmacotherapy classes for Long COVID symptom burden, or (2) to determine if management of neuropsychiatric comorbidities alleviates overall Long COVID burden.

Some study interpretations limited due to study setting

The results of this study highlight considerations of stress and anxiety in Long COVID patients. Given the retrospective study criteria and nature of the data collection, we are unable to temporally resolve the onset of Long COVID symptomatology with any measure considered in this study, including neuropsychiatric symptom burden as measured with validated instruments and the impact of pharmacotherapy on the same scales. We can neither confirm nor assume that all patients would have started prescriptions before initial COVID-19 infection, nor at some point along the development of Long COVID symptomatology. The latter would particularly impact patients with the greatest duration of Long COVID symptoms, as it leaves the greatest chance and window for seeking symptomatic treatment with any of the medication classes analyzed. Importantly, we also cannot rule out the impact of greater socioeconomic stressors experienced by historically marginalized groups on Long COVID Symptom Score, nor any measure of stress and anxiety used here. Our results reflect patient status captured within a single visit to a Rehabilitation Medicine clinic and thus would likely benefit from long-term follow-up with increased sample size.

Materials and Methods

This study was conducted under the approval of the Office of the Institutional Review Board at the University of Texas Health Science Center at San Antonio Long School of Medicine (protocol #20210194EX). Participants in this retrospective cohort study were men and women who were evaluated in a Rehabilitation Medicine outpatient clinic in South Texas from January 2020 to July 2021.
The study setting was an outpatient physiatry clinic in which each participant was evaluated, in a private room, by clinicians for Long COVID symptomatology and administered screening tools for stress, anxiety, and quality of life measures. The data was retrospectively collected directly from the medical chart in the University of Texas at San Antonio Health Science Center's Electronic Medical Record (EPIC). Responses were recorded directly into RedCap and then aggregated in a de-identified database for statistical analysis.

Analytical Population

Eligible participants included patients over the age of 18 years old with a history of acute COVID-19 infection confirmed either by positive COVID-19 test (89%) or evaluation by a clinician for COVID-19 symptoms. Patients were seen at varying periods post-COVID-19 infection. Participants were ineligible if they were younger than 18 years old, did not have a history of acute COVID-19 infection, were evaluated for conditions apart from Long COVID, or were unable to read or speak in English to complete screening tools and clinical evaluation.

During the study period, 235 patients were clinically evaluated. In our analysis, we excluded patients who either did not complete the PTSD Checklist-Civilian Version 5 (PCL-5), Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder Scale 7 (GAD-7), or Satisfaction with Life Scale (SWLS). Patients were not excluded from analysis if they were missing information on other patient factors or screening tools. We excluded these individuals from some sub-analyses ("Missing"), as noted throughout this report. The final analytical sample included 162 patients. These screening tools are outlined in detail below.

Patient Factors

In addition to the above outlined measures, we also collected patient factors for use as covariates in this study (Table 1). Patient factors included biological sex, ethnicity/race, age, education level, body mass index (BMI), pre-existing psychiatric disorders, current medication list, type of health care institution, region, and employment status.

Long COVID Symptom Score

We collected self-reported Long COVID symptomatology noted in the medical record from a single clinical evaluation of Long COVID symptoms (9,11) from all participants. Long COVID symptoms included: (1) positive COVID-19 test at the time of primary infection, (2) fatigue, (3) coughing or shortness of breath (SOB), (4) muscle or joint ache, (5) headache, (6) increased time spent in bed, (7) fever, (8) loss of smell, (9) loss of taste, (10) cognitive impairment, (11) insomnia or sleep disturbance, (12) weight loss, (13) diarrhea, (14) nausea or vomiting, (15) rash, (16) currently exercising. For our analysis, we then operationalized Long COVID symptoms and calculated a Symptom Score based on the total number of symptoms reported during clinical evaluation. We also evaluated factors thought to affect PASC symptom severity, such as the amount of elapsed time from Long COVID evaluation to initial acute COVID-19 infection, whether the patient was hospitalized, required ventilation or supplemental oxygen, or experienced cardiac damage because of primary infection.

Stress and Posttraumatic Stress Disorder (PTSD) Assessment (PCL-5)

Posttraumatic stress disorder (PTSD) Check List for DSM-5 (PCL-5 (37,38)) was used to assess stress and trauma-related symptoms. The PCL-5 was adapted for the Diagnostic and Statistical Manual of Mental Disorders- Fifth Edition (DSM-5) and demonstrated strong reliability and validity (39). The PCL-5 is a 20-item inventory designed to gauge symptoms based on 4 major PTSD symptom clusters: Cluster B (The traumatic event is persistently experienced), Cluster C (Avoidance of trauma-related stimuli after trauma), Cluster D (Negative thoughts or feelings began or worsened after the trauma), Cluster E (Trama-related arousal and reactivity that began or worsened after the trauma. Participants rated the degree to which they experienced each symptom on a scale ranging from 1 (not at all) to 5 (extremely), with possible scores ranging from 17 to 85. Cut scores range from 30 to 60 depending on the variation and base rate of the disorder in the population and settings, and it is recommended to use higher cut-offs in populations with higher base rates, such as veterans, and lower cut scores with populations of lower base rates of PTSD (40). A total score of 31-33 suggests a diagnosis of PTSD and that the patient may benefit from PTSD treatment.

Anxiety Assessment (GAD-7)

We used the Generalized Anxiety Disorder-7 (GAD-7 (41)) to evaluate patients for presence and severity of anxiety. The GAD-7 is a self-report seven item questionnaire assessing symptoms of generalized anxiety disorder that has been found to have validity as a measure of anxiety in the general population (42). In this study, the GAD-7 was altered to reflect symptomatology within the time frame of the past month to match the frame of reference for other screening tools used in this study. GAD-7 scores were used to assign patients into standard categories based on anxiety-related symptoms: 0-4 = minimal anxiety, 5-9 = mild anxiety, 10-14 = moderate anxiety, 15-21 = severe anxiety.

Depression Assessment (PHQ-9)
We used the 9-item Patient Health Questionnaire (PHQ-9 (43)) to evaluate patients for presence and severity of depression. The PHQ-9 has a cut score of 6 that has been recommended for depression screening in primary care and a score of 10 or higher is used to detect symptoms of major depressive disorder (44).

Satisfaction with Life Assessment
The Satisfaction with Life Scale (SWL (45)) is a five item self-report Likert scale ("strongly disagree" to "strongly agree") to measure satisfaction with life as a proxy for subjective well-being. Past studies have established adequate reliability and predictive validity in a wide range of age groups (46). We analyzed patients who fell within categorical score ranges.

Statistical Analysis
We used open-source statistical software (R version 4.3+, Vienna, Austria) to complete all statistical analyses in this study. Patient factors were tested for associations with Symptom Score by stratifying participants as above or below the median symptom score and using the Wilcoxon rank sum test (continuous variables) or Fisher's exact test (categorical variables). Medication use for each category was used as a predictor within linear regression models for each outcome (PCL-5, GAD-7, PHQ-9, and Symptom Score). Spearman's correlations were used to identify associations amongst these outcomes. All testing was two-sided ($\alpha = 0.05$).

References

1. WHO Director-General's opening remarks at the media briefing – 5 May 2023 [Internet]. [cited 2024 Aug 1]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing---5-may-2023

2. Meyerowitz EA, Scott J, Richterman A, Male V, Cevik M. Clinical course and management of COVID-19 in the era of widespread population immunity. Nature Reviews Microbiology 2023 22:2 [Internet]. 2023 Dec 19 [cited 2024 Aug 1];22(2):75–88. Available from: https://www.nature.com/articles/s41579-023-01001-1

3. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls [Internet]. 2023 Aug 18 [cited 2024 Aug 1]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/

4. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA Netw Open [Internet]. 2021 Oct 1 [cited 2024 Aug 1];4(10):e2128568–e2128568. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784918

5. Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA [Internet]. 2023 Jun 13 [cited 2024 Aug 1];329(22):1934–46. Available from: https://jamanetwork.com/journals/jama/fullarticle/2805540

6. National Academies of Sciences E and M. A Long COVID Definition: A Chronic, Systemic Disease State with Profound Consequences. A Long COVID Definition. 2024 Jun 11;

7. Reese JT, Blau H, Casiraghi E, Bergquist T, Loomba JJ, Callahan TJ, et al. Generalisable long COVID subtypes: Findings from the NIH N3C and RECOVER programmes. EBioMedicine [Internet]. 2023 Jan 1 [cited 2024 Aug 1];87:104413. Available from: /pmc/articles/PMC9769411/

8. Danesh V, Arroliga AC, Bourgeois JA, Boehm LM, McNeal MJ, Widmer AJ, et al. Symptom Clusters Seen in Adult COVID-19 Recovery Clinic Care Seekers. J Gen Intern Med [Internet]. 2023 Feb 1 [cited 2024 Aug 1];38(2):442. Available from: /pmc/articles/PMC9663188/

9. Cai M, Xie Y, Topol EJ, Al-Aly Z. Three-year outcomes of post-acute sequelae of COVID-19. Nature Medicine 2024 30:6 [Internet]. 2024 May 30 [cited 2024 Aug 1];30(6):1564–73. Available from: https://www.nature.com/articles/s41591-024-02987-8

10. Bell ML, Catalfamo CJ, Farland L V., Ernst KC, Jacobs ET, Klimentidis YC, et al. Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT. PLoS One [Internet]. 2021 Aug 1 [cited 2024 Aug 1];16(8):e0254347. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0254347

11. Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nature Medicine 2023 29:9 [Internet]. 2023 Aug 21 [cited 2024 Aug 1];29(9):2347–57. Available from: https://www.nature.com/articles/s41591-023-02521-2

12. Peter RS, Nieters A, Kräusslich HG, Brockmann SO, Göpel S, Kindle G, et al. Post-acute sequelae of covid-19 six to 12 months after infection: population based study. BMJ [Internet]. 2022 Oct 13 [cited 2024 Aug 1];379. Available from: https://www.bmj.com/content/379/bmj-2022-071050

13. Bauer L, Laksono BM, de Vrij FMS, Kushner SA, Harschnitz O, van Riel D. The neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2. Trends Neurosci [Internet]. 2022 May 1 [cited 2025 Jun 9];45(5):358. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8890977/

14. Wisk LE, Gottlieb M, Chen P, Yu H, O'Laughlin KN, Stephens KA, et al. Association of SARS-CoV-2 With Health-related Quality of Life 1 Year After Illness Using Latent Transition Analysis. Open Forum Infect Dis [Internet]. 2025 May 31 [cited 2025 Jun 10];12(6). Available from: https://dx.doi.org/10.1093/ofid/ofaf278

15. Cutler DM. The Costs of Long COVID. JAMA Health Forum [Internet]. 2022 May 12 [cited 2024 Aug 1];3(5). Available from: https://pubmed.ncbi.nlm.nih.gov/36219031/

16. Wang C, Ramasamy A, Verduzco-Gutierrez M, Brode WM, Melamed E. Acute and post-acute sequelae of SARS-CoV-2 infection: a review of risk factors and social determinants. Virol J [Internet]. 2023 Dec 1 [cited 2024 Aug 1];20(1):1–11. Available from: https://virologyj.biomedcentral.com/articles/10.1186/s12985-023-02061-8

17. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol [Internet]. 2023 Mar 1 [cited 2024 Aug 1];21(3):133–46. Available from: https://pubmed.ncbi.nlm.nih.gov/36639608/

18. Estrada L V., Levasseur JL, Maxim A, Benavidez GA, Porter KMP. Structural Racism, Place, and COVID-19: A Narrative Review Describing How We Prepare for an Endemic COVID-19 Future. Health Equity [Internet]. 2022 May 1 [cited 2024 Aug 1];6(1):356. Available from: /pmc/articles/PMC9148659/

19. Kantamneni N. The impact of the COVID-19 pandemic on marginalized populations in the United States: A research agenda. J Vocat Behav [Internet]. 2020 Jun 1 [cited 2024 Aug 1];119:103439. Available from: /pmc/articles/PMC7205696/

20. Munipalli B, Ma Y, Li Z, Ganesh R, Knight D, Logvinov II, et al. Risk factors for post-acute sequelae of COVID-19: Survey results from a tertiary care hospital. https://doi.org/101177/10815589231190560 [Internet]. 2023 Aug 12 [cited 2024 Aug 1];71(8):896–906. Available from: https://journals.sagepub.com/doi/abs/10.1177/10815589231190560

21. Shah DP, Thaweethai T, Karlson EW, Bonilla H, Horne BD, Mullington JM, et al. Sex Differences in Long COVID. JAMA Netw Open [Internet]. 2025 Jan 2 [cited 2025 Jun 9];8(1):e2455430–e2455430. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829454

22. Núñez I, Gillard J, Fragoso-Saavedra S, Feyaerts D, Islas-Weinstein L, Gallegos-Guzmán AA, et al. Longitudinal clinical phenotyping of post COVID condition in Mexican adults recovering from severe COVID-19: a prospective cohort study. Front Med (Lausanne) [Internet]. 2023 [cited 2025 Jun 9];10. Available from: https://pubmed.ncbi.nlm.nih.gov/37727759/

23. Hu W, Tang R, Gong S, Liu J, Li J, Liao C. The Prevalence and Associated Factors of Post-COVID-19 Fatigue: A Systematic Review and Meta-Analysis. Cureus [Internet]. 2024 Jul 2 [cited 2024 Aug 1];16(7). Available from: https://pubmed.ncbi.nlm.nih.gov/39092372/

24. Roy D, Ghosh R, Dubey S, Dubey MJ, Benito-Leon J, Kanti Ray B. Neurological and Neuropsychiatric Impacts of COVID-19 Pandemic. Can J Neurol Sci [Internet]. 2021 Jan 1 [cited 2024 Aug 21];48(1):9–24. Available from: https://pubmed.ncbi.nlm.nih.gov/32753076/

25. Song WJ, Hui CKM, Hull JH, Birring SS, McGarvey L, Mazzone SB, et al. Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respir Med [Internet]. 2021 May 1 [cited 2024 Aug 21];9(5):533–44. Available from: https://pubmed.ncbi.nlm.nih.gov/33857435/

26. Sarubbo F, El Haji K, Vidal-Balle A, Bargay Lleonart J. Neurological consequences of COVID-19 and brain related pathogenic mechanisms: A new challenge for neuroscience. Brain Behav Immun Health [Internet]. 2022 Feb 1 [cited 2024 Aug 21];19. Available from: /pmc/articles/PMC8629776/

27. Singh D, Singh E. An overview of the neurological aspects in COVID-19 infection. J Chem Neuroanat [Internet]. 2022 Jul 1 [cited 2024 Aug 21];122:102101. Available from: /pmc/articles/PMC9008979/

28. Coleman B, Casiraghi E, Callahan TJ, Blau H, Chan LE, Laraway B, et al. Association of post-COVID phenotypic manifestations with new-onset psychiatric disease. Translational Psychiatry 2024 14:1 [Internet]. 2024 Jun 8 [cited 2024 Aug 1];14(1):1–9. Available from: https://www.nature.com/articles/s41398-024-02967-z

29. Paez AF, Nicolalde B, Esquetini-Vernon C, Lara-Taranchenko Y, Zambrano K, Ocampo J, et al. Psychiatric disorders in Post-acute COVID-syndrome (PDPACS): Recommendations for health care professionals. European Neuropsychopharmacology [Internet]. 2022 May 1 [cited 2024 Aug 1];58:100. Available from: /pmc/articles/PMC8956896/

30. Ajčević M, Iscra K, Furlanis G, Michelutti M, Miladinović A, Buoite Stella A, et al. Cerebral hypoperfusion in post-COVID-19 cognitively impaired subjects revealed by arterial spin labeling MRI. Scientific Reports 2023 13:1 [Internet]. 2023 Apr 10 [cited 2024 Aug 21];13(1):1–9. Available from: https://www.nature.com/articles/s41598-023-32275-3

31. Braga J, Lepra M, Kish SJ, Rusjan PM, Nasser Z, Verhoeff N, et al. Neuroinflammation After COVID-19 With Persistent Depressive and Cognitive Symptoms. JAMA Psychiatry [Internet]. 2023

Aug 1 [cited 2024 Aug 21];80(8):787–95. Available from: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2805366

32. VanElzakker MB, Bues HF, Brusaferri L, Kim M, Saadi D, Ratai EM, et al. Neuroinflammation in post-acute sequelae of COVID-19 (PASC) as assessed by [11C]PBR28 PET correlates with vascular disease measures. Brain Behav Immun [Internet]. 2024 Jul 1 [cited 2024 Aug 21];119:713. Available from: /pmc/articles/PMC11225883/

33. Cecchetti G, Agosta F, Canu E, Basaia S, Barbieri A, Cardamone R, et al. Cognitive, EEG, and MRI features of COVID-19 survivors: a 10-month study. J Neurol [Internet]. 2022 Jul 1 [cited 2024 Aug 21];269(7):3400–12. Available from: https://pubmed.ncbi.nlm.nih.gov/35249144/

34. Chen B, Chen C, Zheng J, Li R, Xu J. Insights Into Neuroimaging Findings of Patients With Coronavirus Disease 2019 Presenting With Neurological Manifestations. Front Neurol [Internet]. 2020 Nov 9 [cited 2024 Aug 21];11:593520. Available from: /pmc/articles/PMC7680864/

35. Huang S, Zhou Z, Yang D, Zhao W, Zeng M, Xie X, et al. Persistent white matter changes in recovered COVID-19 patients at the 1-year follow-up. Brain [Internet]. 2022 Jun 3 [cited 2024 Aug 21];145(5):1830–8. Available from: https://dx.doi.org/10.1093/brain/awab435

36. Lee YS, Kim H, Kwon S, Kim TH. Association between long COVID and nonsteroidal anti-inflammatory drug use by patients with acute-phase COVID-19: A nationwide Korea National Health Insurance Service cohort study. PLoS One [Internet]. 2024 Nov 1 [cited 2025 Jun 9];19(11):e0312530. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0312530

37. Weathers FW, LBT, KTM, PPA, MBP, & SPP. www.ptsd.va.gov. 2013. The PTSD Checklist for DSM-5 (PCL-5).

38. Forkus SR, Raudales AM, Rafiuddin HS, Weiss NH, Messman BA, Contractor AA. The Posttraumatic Stress Disorder (PTSD) Checklist for DSM–5: A Systematic Review of Existing Psychometric Evidence. Clin Psychol (New York) [Internet]. 2023 Sep 8 [cited 2024 Aug 1];30(1):110. Available from: /pmc/articles/PMC10292741/

39. Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation. J Trauma Stress [Internet]. 2015 Dec 1 [cited 2024 Aug 1];28(6):489–98. Available from: https://pubmed.ncbi.nlm.nih.gov/26606250/

40. McDonald SD, Calhoun PS. The diagnostic accuracy of the PTSD checklist: a critical review. Clin Psychol Rev [Internet]. 2010 Dec [cited 2024 Aug 1];30(8):976–87. Available from: https://pubmed.ncbi.nlm.nih.gov/20705376/

41. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med [Internet]. 2006 May 22 [cited 2024 Aug 1];166(10):1092–7. Available from: https://pubmed.ncbi.nlm.nih.gov/16717171/

42. Löwe B, Decker O, Müller S, Brähler E, Schellberg D, Herzog W, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care [Internet]. 2008 Feb [cited 2024 Aug 1];46(3):266–74. Available from: https://pubmed.ncbi.nlm.nih.gov/18388841/

43. Spitzer RL, Kroenke K, Williams JBW. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA [Internet]. 1999 Nov 10 [cited 2024 Aug 21];282(18):1737–44. Available from: https://pubmed.ncbi.nlm.nih.gov/10568646/

44. Arroll B, Goodyear-Smith F, Crengle S, Gunn J, Kerse N, Fishman T, et al. Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population. Ann Fam Med [Internet]. 2010 [cited 2024 Aug 21];8(4):348–53. Available from: https://pubmed.ncbi.nlm.nih.gov/20644190/

45. Diener E, Emmons RA, Larsem RJ, Griffin S. The Satisfaction With Life Scale. J Pers Assess [Internet]. 1985 Feb 1 [cited 2024 Aug 1];49(1):71–5. Available from: https://pubmed.ncbi.nlm.nih.gov/16367493/

46. Pavot W, Diener E, Colvin CR, Sandvik E. Further validation of the Satisfaction with Life Scale: evidence for the cross-method convergence of well-being measures. J Pers Assess [Internet]. 1991 [cited 2024 Aug 1];57(1):149–61. Available from: https://pubmed.ncbi.nlm.nih.gov/1920028/

615 **Figure Captions**
616
617 **Figure 1. Summary of Symptom Score Components and incidence (%) in analytical sample.** We
618 collected self-reported data on PASC symptomatology across all major systems as previously described
619 (Bowe et al 2023; Cai et al 2024). Symptoms were ranked by incidence (% of patients who reported
620 symptom) in our sample. We then calculated a PASC Symptom Score based on the total number of
621 comorbid symptoms present in a patient based on the top 16 most common symptoms, summarized here.
622 Of note, the most common PASC symptoms noted by our sample was fatigue (93%). There was a high
623 burden of symptoms classically related to acute COVID-19 infection (coughing, shortness of breath
624 [SOB], loss of smell and taste) as well as subjective neuropsychiatric symptoms (cognitive impairment =
625 79%, muscle/joint pain = 78%, insomnia/sleep disturbance = 58%).
626
627 **Figure 2. Correlation of Symptom Score with measures of depression (PHQ-9), stress (PCL-5), and**
628 **anxiety (GAD-7) symptoms.** We assessed whether PASC Symptom Scores were correlated with the
629 presence of depression, stress, or anxiety symptomatology as determined by validated screening tools.
630 Spearman rank correlations were computed for each pairwise combination of PASC Symptom Score and
631 PCL-5 or GAD-7 scores. PHQ-9, PCL-5, and GAD-7 scores were mutually associated. PASC Symptom
632 Score was positively associated with PHQ-9 (0.218, $p < 0.05$), GAD-7 ($r = 0.29$, $p < 0.05$) and PCL-5 ($r =$
633 0.25, $p < 0.05$).
634
635 **Figure 3. Correlation of individual PCL-5 items with Long COVID Symptoms.** Spearman rank
636 correlations were calculated for the intersection of the score of each item, reflecting frequency of stress
637 and PSTD-related symptoms by item of the PCL-5 and the PASC symptoms used to calculate PASC
638 Symptom Score. We contextualize the PCL-5 item scores with their respective symptom clusters for Post-
639 Traumatic Stress Disorder according to the DSM-5, designated to the left of each PCL-5 item: Cluster B
640 (The traumatic event is persistently experienced), Cluster C (Avoidance of trauma-related stimuli after
641 trauma), Cluster D (Negative thoughts or feelings began or worsened after the trauma), Cluster E (Trama-
642 related arousal and reactivity that began or worsened after the trauma. Correlations are given for all
643 findings with $p < 0.05$.
644
645 **Figure 4. Correlation of depression (PHQ-9), anxiety (GAD-7), and stress (PCL-5) symptomatology**
646 **with current medications.** Spearman rank correlations were calculated for the intersection of {HQ-9,
647 GAD-7, and PCL-5 total scores with classes of current medications endorsed by self-report. Correlations
648 are given for all findings with $p < 0.05$.
649
650

651 **Tables**

652

653 **Table 1. Summary of patient factors and prediction of Long COVID Symptom Score.**

		PASC Symptom Score		
Patient Factor	**Overall**, N = 162[1]	**> Median**, N = 78[1]	**≤ Median**, N = 84[1]	**p-value**[2]
Symptom Score	9 (8, 11)	11 (10, 12)	8 (6, 8)	<0.001
Sex				0.2
Female	117 (73%)	60 (78%)	57 (68%)	
Male	44 (27%)	17 (22%)	27 (32%)	
(Missing)	1	1	0	
Age at Evaluation	44 (35, 54)	44 (36, 52)	46 (34, 56)	0.4
BMI	30 (26, 36)	30 (26, 35)	29 (26, 36)	0.7
(Missing)	22	12	10	
Race/Ethnicity[3]				0.8
Black or African American	6 (3.9%)	4 (5.3%)	2 (2.6%)	
White	61 (40%)	29 (39%)	32 (42%)	
Hispanic	78 (51%)	38 (51%)	40 (52%)	
Other	7 (4.6%)	4 (5.3%)	3 (3.9%)	
(Missing)	10	3	7	
Time since infection (Days)	190 (83, 278)	218 (83, 295)	169 (95, 264)	0.4
(Missing)	5	0	5	
Time since infection < 30 Days	8 (5.1%)	1 (1.3%)	7 (8.9%)	0.063
(Missing)	5	0	5	

[1] Median (IQR); N (%)

[2] Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test (categorical variables)

[3] Other includes: American Indian Alaska Native, Asian. Unknown set to Missing

654

655

656 **Table 2. Categorical score results of screening tools for stress (PCL-5), anxiety (GAD-7), and**
657 **depression (PHQ-9) symptoms, and satisfaction with life (SWL) in Long COVID patients.**

PCL-5 Score (N = 162)	**N (%)**
Not elevated	90 (56%)
Significantly elevated trauma symptoms of PTSD	72 (44%)
GAD-7 Score (N = 143)	**N (%)**
No Significant Symptoms	44 (31%)
Mild	38 (27%)
Moderate	35 (24%)
Severe	26 (18%)
(Missing)	19
PHQ-9 Score (N = 146)	**N (%)**
Minimal Depression	38 (26%)
Mild Depression	32 (22%)
Moderate Depression	34 (23%)
Moderately Severe Depression	21 (14%)
Severe Depression	21 (14%)
(Missing)	16
SWL Score (N = 147)	**N (%)**
Dissatisfied	11 (7.5%)
Extremely dissatisfied	14 (9.5%)
Extremely satisfied	18 (12%)
Neutral	4 (2.7%)
Satisfied	39 (27%)
Slightly dissatisfied	35 (24%)
Slightly satisfied	26 (18%)
(Missing)	15

658
659
660
661

662 **Table 3. Correlation of anxiety, stress, and depression symptomatology with mood stabilizer and**
663 **stimulant class medications.**

	Mood Stabilizer Class				
Characteristic	**Yes**, N = 6[1]	**No**, N = 156[1]	**Difference**[2]	**95% CI**[2,3]	**p-value**[2]
GAD-7 Score	15.8 (6.3)	8.2 (6.0)	7.6	1.0, 14	0.031
(Missing)	0	19			
PCL-5 Score	54 (23)	30 (21)	24	-0.49, 48	0.053
PHQ-9 Score	18 (7)	10 (7)	7.9	0.89, 15	0.034
(Missing)	0	16			
	Stimulant Class				
Characteristic	**Yes**, N = 8[1]	**No**, N = 154[1]	**Difference**[2]	**95% CI**[2,3]	**p-value**[2]
GAD-7 Score	13.1 (4.7)	8.3 (6.1)	4.9	0.46, 9.3	0.035
(Missing)	1	18			
PCL-5 Score	48 (23)	30 (21)	18	-1.7, 37	0.068
PHQ-9 Score	17 (5)	10 (7)	7.1	2.4, 12	0.009
(Missing)	1	15			

[1] Mean (SD)

[2] Welch Two Sample t-test

[3] CI = Confidence Interval

664


Fatigue
150 (93%)
Positive COVID 19 test
144 (89%)
Coughing SOB
132 (81%)
Cognitive impairment
128 (79%)
Muscle joint achesized
126 (78%)
Headache
120 (74%)
Increased Time spent in bed
118 (73%)
Fever
108 (67%)
Loss of smell
94 (58%)
Insomnia or Sleep Disturbance
94 (58%)
Weight loss
91 (56%)
Loss of taste
88 (54%)
Diarrhea
70 (43%)
Nausea Vomiting
61 (38%)
Currently Exercising
40 (25%)
Rash
34 (21%)
Symptom
0
50
100
150
n


GAD.7.Total.Score
PCL.5.Total_comb
PHQ_9.Total
Symptom_Score
Corr:
0.689***
Corr:
0.776***
Corr:
0.289***
Corr:
0.704***
Corr:
0.253**
Corr:
0.218**


DSM-5 PTSD Symptom Cluster
B
C
D
E
PCL 5 Total_comb
PCL 5 Item 1 n
PCL 5 Item 2 n
PCL 5 Item 3 n
PCL 5 Item 4 n
PCL 5 Item 5 n
PCL 5 Item 6 n
PCL 5 Item 7 n
PCL 5 Item 8 n
PCL 5 Item 9 n
PCL 5 Item 10 n
PCL 5 Item 11 n
PCL 5 Item 12 n
PCL 5 Item 13 n
PCL 5 Item 14 n
PCL 5 Item 15 n
PCL 5 Item 16 n
PCL 5 Item 17 n
PCL 5 Item 18 n
PCL 5 Item 19 n
PCL 5 Item 20 n
Insomnia or Sleep Disturbance
Symptom_Score
Headache
Cognitive impairment
Diarrhea
Rash
Currently Exercising
Loss of smell
Muscle joint achesized
Fatigue
Nausea Vomiting
Weight loss
Coughing SOB
Fever
Increased Time spent in bed
Loss of taste
Positive COVID 19 test
Corr
-1.0 -0.5 0.0 0.5 1.0


PHQ_9.Total
GAD.7.Total.Score
PCL.5.Total_comb
0.2
0.2
0.2
0.2
0.3
0.2
-0.2
anxiolytic
stimulant
analgesics
antipyretics
antibiotics
mood stabilizers
tranquilizers
benzodiazepine
statins
hormone replacement
contraceptive
blood pressure
insulin
coagulation
digestive
thyroid
respiratory
antihistamine
muscle relaxant
myoclonal antibodies
immunosuppressants
anticonvulsant
beta blocker
none of these
Corr
-1.0
-0.5
0.0
0.5
1.0